Bone marrow concentrate: a novel strategy for bone defect treatment.

Background: Although strong efforts have been made over the last decade to introduce stem cell and tissue engineering treatment strategies to the field of orthopaedics, only few clinical applications are currently available.

Materials And Methods: The clinical outcomes of ten patients with volumetric bone deficiencies treated with mesenchymal stem cells and bone marrow aspirate are presented in this case series. Results were evaluated with radiographs.

Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity.

Stem and progenitor cell therapy is a novel strategy to enhance cardiovascular regeneration. Cell isolation procedures are crucial for the functional activity of the administered cellular product. Therefore, new isolation techniques have to be evaluated in comparison to the Ficoll isolation procedure as the current gold standard.

Concentration of Bone Marrow Total Nucleated Cells by a Point-of-Care Device Provides a High Yield and Preserves Their Functional Activity.

Stem and progenitor cell therapy is a novel strategy to enhance cardiovascular regeneration. Cell isolation procedures are crucial for the functional activity of the administered cellular product. Therefore, new isolation techniques have to be evaluated in comparison to the Ficoll isolation procedure as the current gold standard.

Use of a centrifugation-based, point-of-care device for production of canine autologous bone marrow and platelet concentrates.

Objective: To analyze a centrifugation-based, point-of-care device that concentrates canine platelets and bone marrow-derived cells.

Animals: 19 adult sexually intact dogs.

Procedures: Anticoagulated peripheral blood (60 mL) and 60 mL of anticoagulated bone marrow aspirate (BMA) were concentrated by centrifugation with the centrifugation-based, point-of-care device to form a platelet and a bone marrow concentrate (BMC) from 11 dogs.

Modulation of wound response and soft tissue ingrowth in synthetic and allogeneic implants with platelet concentrate.

Objective: To evaluate the modulation of wound healing and soft tissue ingrowth in synthetic and allogeneic implants with platelet gel. Attempts to influence wound healing with exogenous growth factors are highly dependent on the timing and dosing of treatment. Platelet gel made from autologous platelet concentrate (PC) and activated with calcium thrombin is increasingly used to enhance healing of surgical and chronic wounds, based on the assumption that proteins found in the blood can promote healing.

Comparison of methods for point of care preparation of autologous platelet gel.

A platelet gel (PG) is produced by the addition of calcium chloride and thrombin to a platelet concentrate (PC). PG releases multiple growth factors, which have the ability to initiate and stimulate one growth factor's function in the presence of others. This finding has resulted in the use of PG in orthopedic, plastic, and reconstructive surgery.

An in vitro and in vivo evaluation of autologous platelet concentrate in oral reconstruction.

A platelet concentrate, when combined with calcified thrombin, produces a platelet gel that has been used to achieve hemostasis and modulate bone growth and wound healing. The recovery of high concentrations of viable platelets and their resulting growth factor levels represents the most important factor in the clinical utility of a platelet concentrate because only functional platelets can release the growth factors that are necessary to induce tissue growth and bone regeneration. The SmartPReP system's efficiency in recovery of platelets from a sample of whole blood averaged 70.